


CLAIMS

1. A compound of formula (I)



5 or a pharmaceutically acceptable salt thereof, wherein

one of X and Y is C and the other one is N;

R₁ is selected from halogen, CN, NH(CH₃), N(CH₃)₂, C1-C4 alkoxy, optionally substituted by 1-3 halogens, and C1-C4 alkyl, optionally substituted by 1-3 halogens, CN, NH(CH₃), or N(CH₃)₂; and

10 R₂ is 3,4-dimethoxyphenyl or 1,3-dimethyl-1*H*-indazol-5-yl.

2. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R₂ is 3,4-dimethoxyphenyl.

15 3. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R₂ is 1,3-dimethyl-1*H*-indazol-5-yl.

4. The compound according to any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof, wherein R₁ is selected from halogen, CN, C1-C4 alkoxy, optionally substituted by 1-3 halogens, and C1-C4 alkyl, optionally substituted by 1-3 halogens.

20 3 halogens, and C1-C4 alkyl, optionally substituted by 1-3 halogens.

5. The compound according to claim 4, or a pharmaceutically acceptable salt thereof, wherein R₁ is selected from F, CN, methoxy, methyl, trifluoromethyl, and ethyl.

25 6. The compound according to claim 4, or a pharmaceutically acceptable salt thereof, wherein R₁ is selected from halogen and C1-C4 alkyl, optionally substituted by 1-3 halogens.

7. The compound according to claim 6, or a pharmaceutically acceptable salt thereof, wherein R₁ is selected from F, methyl, trifluoromethyl, and ethyl.

8. The compound according to any one of claims 1 to 7, wherein X is N, and Y is C.

9. The compound according to any one of claims 1 to 7, wherein X is C, and Y is N.

5

10. A compound according to claim 1, selected from

3-(3,4-dimethoxyphenyl)-2,6-dimethyl-N-((2-methylpyridin-4-yl)methyl)imidazo[1,2-b]pyridazin-8-amine,

3-(3,4-dimethoxyphenyl)-N-((2-fluoropyridin-4-yl)methyl)-2,6-dimethylimidazo[1,2-

10 b]pyridazin-8-amine,

3-(1,3-dimethyl-1H-indazol-5-yl)-2,5-dimethyl-N-[(2-fluoropyridin-4-yl)methyl]pyrazolo[1,5-a]pyrimidin-7-amine, and

3-(1,3-dimethyl-1H-indazol-5-yl)-2,5-dimethyl-N-[(2-methylpyridin-4-yl)methyl]pyrazolo[1,5-a]pyrimidin-7-amine,

15 3-(1,3-dimethyl-1H-indazol-5-yl)-2,5-dimethyl-N-[(2-ethylpyridin-4-yl)methyl]pyrazolo[1,5-a]pyrimidin-7-amine,

3-(1,3-dimethyl-1H-indazol-5-yl)-2,5-dimethyl-N-[(2-methoxypyridin-4-yl)methyl]pyrazolo[1,5-a]pyrimidin-7-amine,

3-(1,3-dimethyl-1H-indazol-5-yl)-2,5-dimethyl-N-[(2-cyanopyridin-4-yl)methyl]pyrazolo[1,5-a]pyrimidin-7-amine, and

20 3-(1,3-dimethyl-1H-indazol-5-yl)-2,5-dimethyl-N-[(2-trifluoromethylpyridin-4-yl)methyl]pyrazolo[1,5-a]pyrimidin-7-amine,

or a pharmaceutically acceptable salt thereof.

25 11. A compound according to any one of claims 1 to 10, or a pharmaceutically acceptable salt thereof, for use in therapy.

12. A pharmaceutical composition comprising a compound according to any one of claims 1 to 10, or a pharmaceutically acceptable salt thereof, and optionally a pharmaceutically acceptable excipient.

30

13. Use of aA compound according to any one of claims 1 to 10, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating use in the treatment of a viral infection or a disease caused by a viral infection.

14. The ~~compound or pharmaceutically acceptable salt for use~~use according to claim 13, wherein the viral infection is an RNA viral infection.

5 15. The ~~compound or pharmaceutically acceptable salt for use~~use according to claim 14, wherein the RNA viral infection is a picornaviral infection.

10 16. The ~~compound or pharmaceutically acceptable salt for use~~use according to any one of claims claim 13 to 15, ~~for the treatment of wherein the disease is selected from~~ pancreatitis, poliomyelitis, encephalitis, meningitis, sepsis, cancer, paralysis, a cardiac disease, diabetes, common cold, hand-foot-and-mouth disease, herpangina, pleurodynia, diarrhea, a mucocutaneous lesion, respiratory illness, conjunctivitis, myositis, chronic fatigue syndrome, neuropsychiatric diseases, neurodegenerative diseases or an inflammatory condition.

15 ~~17. Use of a compound or pharmaceutically acceptable salt according to any one of claims 1 to 10, in the manufacture of a medicament for the treatment of a viral infection.~~

~~18. The use according to claim 17, wherein the viral infection is an RNA viral infection.~~

20 ~~19. The use according to claim 18, wherein the RNA viral infection is a picornaviral infection.~~

~~20. The use according to any one of claims 17 to 19, wherein the medicament is for the treatment of pancreatitis, poliomyelitis, encephalitis, meningitis, sepsis, cancer, paralysis, a cardiac disease, diabetes, common cold, hand foot and mouth disease, herpangina,~~
 25 ~~pleurodynia, diarrhea, a mucocutaneous lesion, respiratory illness, conjunctivitis, myositis, chronic fatigue syndrome, a neuropsychiatric disease, a neurodegenerative disease or an inflammatory condition.~~

~~21. A method for the treatment of a viral infection in a mammal, which comprises administering an effective amount of the compound or pharmaceutically acceptable salt according to any one of claims 1 to 10 to the mammal.~~

30

~~22. The method of claim 21, wherein the viral infection is an RNA viral infection.~~

~~23. The method of claim 22, wherein the RNA viral infection is a picornaviral infection.~~

~~24. The method of any one of claims 21 to 23, for the treatment of pancreatitis, poliomyelitis, encephalitis, meningitis, sepsis, cancer, paralysis, a cardiac disease, diabetes, common cold, hand-foot-and-mouth disease, herpangina, pleurodynia, diarrhea, a mucocutaneous lesion, respiratory illness, conjunctivitis, myositis, chronic fatigue syndrome, a neuropsychiatric disease, a neurodegenerative disease or an inflammatory condition.~~

5